
医疗技术初创公司Science Corporation在一篇博客文章中表示,该公司完成了4亿美元的D轮融资。Science Corporation由前Neuralink总裁Max Hodak于2021年创立。
Science Corporation, the medical technology start-up founded by former Neuralink president Max Hodak in 2021, raised a $400 million Series D, the company said in a blog post.
一位知情人士告诉TechCrunch,投资方在新一轮融资中给Science Corporation的估值为35亿美元。投资方包括Khosla Ventures、Ackman Oxman Institute、Tenet Healthcare、885 Capital、Y Combinator和PLC Neurotech。
Investors in the new round valued the company at $3.5 billion, a person familiar with the deal told TechCrunch. Those backers included Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech.
Hodak大学时期通过交谈进入了一个研究生神经科学实验室,此后一直从事生物技术工作。他联合创立Science Corporation,旨在利用新技术来理解和与大脑互动。
Hodak, who talked his way into a graduate neuroscience lab as a college student and has pursued biotechnology ever since, co-founded Science to leverage new technologies to understand and interact with the brain.
Science Corporation的首款产品是PRIMA,这是一种可穿戴和可植入的芯片,可帮助患有老年性黄斑变性的人恢复部分视力。该设备已在欧洲获批,并在德国上市,同时也在针对新病症进行试验。
Science’s first product is PRIMA, a wearable and implantable chip that helps people with age-related macular degeneration recover some vision. The device is approved in Europe and available in Germany, as well as being trialled for new conditions.
Hodak在TechCrunch Disrupt大会上宣布,该设备目前正在针对另一种致盲疾病——Stargardt病(施塔格特氏病)患者进行试验。
Hodak announced that the device is now being trialled for patients with another blindness-causing condition, Stargardt’s disease, while onstage at TechCrunch Disrupt.
有了这笔资金,公司计划通过FDA的“人道主义设备豁免”将该设备引入美国,该豁免允许实验性医疗技术用于治疗罕见病症。Science Corporation已说服FDA,双眼晚期黄斑变性足够罕见,符合申请在美国对人体使用该设备的批准条件。
With the funding, the company aims to bring the device to the United States through the FDA’s Humanitarian Device Exemption, which lets experimental medical technology be used to treat rare conditions. Science has convinced the FDA that advanced macular degeneration in both eyes is uncommon enough to let them seek approval to use the device on people in the US.

尽管如此,这家初创公司的宏大雄心和创立初衷,是通过一种由培养神经元和硅结合而成的生物混合传感器,直接与人脑连接。公司目前正在与耶鲁大学神经外科教授Murat Günel设计该设备的初步人体试验,Günel告诉TechCrunch,该设备可能为帕金森病等脑损伤和疾病提供潜在治疗方案。
Still, the startup’s big ambition and founding purpose is connecting directly to the human brain through a bio-hybrid sensor built from a combination of cultured neurons and silicon. The company is currently designing initial human trials of the device with Yale neurosurgery professor Murat Günel, who told TechCrunch it could offer potential treatments for Parkinson’s disease, among other brain injuries and illnesses.

